银屑病全身治疗的遗传药理学进展  

Advances in pharmacogenetics of systemic therapies for psoriasis

作　　者：孟祥光[1] 倪文琼[2] 王超 马登轩 李智[1] 周宏灏[1] 

机构地区：[1]中南大学临床药理研究所 [2]郑州市中心医院 [3]周口市食品药品检验所 [4]开封朱仙镇卫生院

出　　处：《中国临床药理学与治疗学》2012年第11期1307-1313,共7页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：银屑病是一种炎症过度增生性皮肤病,有强烈的遗传易感性。主要受到遗传、免疫和环境的影响。由于部分患者病情处于中重度,局部治疗效果不佳,所以必须施以全身治疗。但全身治疗费用高且疗效和毒性个体化差异大,因此,涉及银屑病全身治疗的遗传药理学研究意义重大。本文主要对近几年银屑病全身治疗和遗传的关系进行一个较为全面的综述,以期为银屑病患者的个体化医学提供理论指导。Psoriasis is an inflammatory by- perproliferative skin disease with a strong genet- ic susceptibility and influenced by genetic, im- munological and environmental factors. Because most patients with moderate to severe psoriasis cannot benefit from the topical treatment, they have to treat with systemic agents. While the systemic treatment is characterized of high medi- cal cost and large inter-individual variations in efficacy and adverse reaction, the studies onpharmacogenetics of systemic therapies for Pso riasis play an important role in clinic. This re- view summarizes the correlations between genet- ic factors and systemic agents to provide the the oretical guidance for the personalized medication in psoriasis.

关 键 词：银屑病 遗传药理学 甲氨蝶呤 环孢素A 阿维A酸 

分 类 号：R751.05[医药卫生—皮肤病学与性病学]